Drug Trial Radar · NCT04518995
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
706
Actual
Start
Nov 23, 2020
Primary completion
Apr 19, 2022
Study completion Apr 19, 2022
Sponsor
- Lead sponsor
- Concert PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
Conditions
- Alopecia Areata
Interventions
CTP-543 matching placeboDrug
Administered as tablets.
CTP-543Drug
Administered as tablets.
CTP-543Drug
Administered as tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24Time frame: Week 24
Locations
72 sites in 5 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center
Birmingham, Alabama
Kern Research, Inc.
Bakersfield, California
California Dermatology & Clinical Research Institute
Encinitas, California
UC Irvine Dermatology Clinical Research Center
Irvine, California
Quest Dermatology Research
Northridge, California
Kaiser Permanente
Oakland, California
Kaiser Permanente South Sacramento
Sacramento, California
Kaiser Permanente
San Francisco, California
Colorado Center for Dermatology and Skin Surgery
Centennial, Colorado
Colorado Medical Research Center
Denver, Colorado
Yale University, Church Street Research Unit
New Haven, Connecticut
Lenus Research & Medical Group, LLC
Sweetwater, Florida
Clinical Research Trials of Florida, Inc.
Tampa, Florida
Forward Clinical Trials Inc.
Tampa, Florida
Denova Research
Chicago, Illinois
Northwestern Memorial Hospital, Department of Dermatology
Chicago, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
DS Research
New Albany, Indiana
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
DS Research
Louisville, Kentucky
Qualmedica Research LLC
Owensboro, Kentucky
Massachusetts General Hospital - Clinic
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Clarkston Skin Research
Clarkston, Michigan
Minnesota Clinical Study Center
Fridley, Minnesota
University of Minnesota Department of Dermatology
Minneapolis, Minnesota
Skin Laser and Surgery Specialists of NJ
Hackensack, New Jersey
Sadick Research Group
New York, New York
Darst Dermatology
Charlotte, North Carolina
Dermatology Specialists of Charlotte
Charlotte, North Carolina
Wake Forest University Health Sciences, Department of Dermatology
Winston-Salem, North Carolina
Bexley Dermatology Research
Bexley, Ohio
Vital Prospects Clinical Research Institute, P.C.
Tulsa, Oklahoma
Northwest Dermatology Institute
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Dermatology Associates Of Plymouth Meeting
Plymouth Meeting, Pennsylvania
PEAK Research
Upper Saint Clair, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Clinical Research Center of the Carolinas
Charleston, South Carolina
Palmetto Clinical Trial Services
Fountain Inn, South Carolina
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.